Darmiyan Launches BrainSee Platform For Alzheimer’s Testing & Risk Monitoring     

Brain technology provider;Darmiyan launched its BrainSee Platform in the United States on September 16, 2024. The platform, which has been approved by the FDA, will be available nationwide. The platform integrates the BrainSee Test for Alzheimer’s disease to help individuals with memory concerns assess and monitor their risk of progression to Alzheimer’s dementia. ;

The non-invasive BrainSee test uses advanced AI algorithms to analyze routine clinical brain MRIs and cognitive test results to identify those with cognitive impairment and memory loss. The AI algorithm provides a numerical score between 0 and 100 to indicate the . . .